Literature DB >> 17405914

Control of human herpes virus type 8-associated diseases by NK cells.

Maria C Sirianni1, Massimo Campagna, Donato Scaramuzzi, Maurizio Carbonari, Elena Toschi, Ilaria Bacigalupo, Paolo Monini, Barbara Ensoli.   

Abstract

The "natural killer" (NK) cells preferentially kill targets lacking surface major histocompatibility complex class I (MHC-I) molecule expression. NK cells recognize these targets through membrane receptors, which can trigger activating or inhibitory signals for killing. Several tumors or virus-infected cells downregulate MHC-I expression as a mechanism to evade recognition and killing by cytotoxic T lymphocytes (CTL). They, however, become targets for NK cells cytotoxic activity. NK cell activity is reduced during disease progression in human immunodeficiency virus (HIV) infection, and in individuals with AIDS-associated tumors linked with infection by the oncogenic human herpes virus type-8 (HHV8), including Kaposi's sarcoma (KS) and primary effusion lymphomas (PEL). We have demonstrated that AIDS-related KS (AIDS-KS) is characterized by an increased expression of inhibitory receptors by T lymphocytes, and that HIV-non-infected patients with KS (classic KS, C-KS) have a substantial number of NK cells bearing these same receptors. NK cells from patients with C-KS are normally equipped with cytolytic molecules including granzyme A and perforin. However, the cytotoxic activity of NK cells is reduced in patients with C-KS, AIDS-KS, or PEL patients, who are all infected by the HHV8, and this correlates with disease severity. Moreover, we have found that HHV8-infected cell lines established from PELs have a reduced surface expression of MHC-I molecules and are sensitive to the lysis mediated by NK cells. Since PEL cells express the same HHV8 latency program as KS cells, these data point to MHC-I downregulation by HHV8 as a primary immune evasion mechanism against CTL responses, further reinforced by upregulation of inhibitory receptors on T and NK cells in the setting of HIV and/or HHV8 infection. Thus, studies on killing receptor regulation and signaling in T and NK cells may shed light on the pathogenesis of HHV8-associated tumors both in HIV-infected or -noninfected patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17405914     DOI: 10.1196/annals.1397.068

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  5 in total

1.  Cerebral Vasculitis in X-linked Lymphoproliferative Disease Cured by Matched Unrelated Cord Blood Transplant.

Authors:  Paul E Gray; Tracey A O'Brien; Mayura Wagle; Stuart G Tangye; Umaimainthan Palendira; Tony Roscioli; Sharon Choo; Rosemary Sutton; John B Ziegler; Katie Frith
Journal:  J Clin Immunol       Date:  2015-10-03       Impact factor: 8.317

2.  The Presence of Antibody-Dependent Cell Cytotoxicity-Mediating Antibodies in Kaposi Sarcoma-Associated Herpesvirus-Seropositive Individuals Does Not Correlate with Disease Pathogenesis or Progression.

Authors:  Lisa K Poppe; Charles Wood; John T West
Journal:  J Immunol       Date:  2020-09-30       Impact factor: 5.422

Review 3.  Natural Killer Cell Responses during Human γ-Herpesvirus Infections.

Authors:  Christian Münz
Journal:  Vaccines (Basel)       Date:  2021-06-15

4.  Impact of Pegylated Interferon-alfa-2a on Perforin Level in Patients With Chronic Hepatitis B; Preliminary Study.

Authors:  Meisam Mahdavi; Houshang Amirrasouli; Seyed Moayed Alavian; Bita Behnava; Faranak Kazerouni; Maryam Keshvari; Saeed Namaki; Mohammad Gholami Fesharaki; Hooman Rahimipour; Jahangir Mohammadzade; Farahnaz Zohrehbandian; Fazel Mahdavipour
Journal:  Hepat Mon       Date:  2013-11-23       Impact factor: 0.660

Review 5.  Baseline and Dynamic Expression of Activating NK Cell Receptors in the Control of Chronic Viral Infections: The Paradigm of HIV-1 and HCV.

Authors:  Francesco Marras; Federica Bozzano; Maria Libera Ascierto; Andrea De Maria
Journal:  Front Immunol       Date:  2014-07-02       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.